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Abstract
Botulism had mortality rates >60% before the 1950s. We reviewed confirmed botulism cases in 
the USA during 1975–2009 including infant, foodborne, wound, and other/unknown acquisition 
categories, and calculated mortality ratios. We created a multivariate logistic regression model for 
non-infant cases (foodborne, wound, and other/unknown). Overall mortality was 3.0% with 109 
botulism-related deaths among 3,618 botulism cases [18 (<1%) deaths among 2,352 infant 
botulism cases, 61 (7.1%) deaths among 854 foodborne botulism cases, 18 (5.0%) deaths among 
359 wound botulism cases, and 12 (22.6%) deaths among 53 other/unknown botulism cases]. 
Mortality among all cases increased with age; it was lowest among infants (0.8%) and highest 
among persons ≥80 years old (34.4%). Toxin type F had higher mortality (13.8%) than types A, B, 
or E (range, 1.4% to 4.1%). Efforts to reduce botulism mortality should target non-infant 
transmission categories and older adults.
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Botulism is a severe illness that is caused by toxin-mediated blockade of acetylcholine 
release across the neuromuscular junction. The resulting flaccid paralysis can be fatal when 
the respiratory muscles are involved. Indeed, >60% of US botulism cases were fatal before 
the 1950s, though the case-fatality ratio gradually declined to <10% by the 1990s due to 
increasing availability of positive pressure mechanical ventilation, botulinum antitoxin, and 
other aspects of intensive supportive care (Centers for Disease Control and Prevention, 1998; 
Puri et al., 2009); intravenous botulism immune globulin for infants became available in 
2003. Though rare, botulism is a medical and public health emergency because of its 
lethality and the possibility that a single non-infant case indicates a larger outbreak; all states 
require immediate reporting of suspect cases. The Centers for Disease Control and 
Prevention (CDC) and the California Department of Health Services (CDHS) provide 
national 24-hour clinical consultation and antitoxin release service for suspected non-infant 
and infant cases, respectively1.
Seven serologically distinct botulinum toxin types (A–G) are known. Human botulism is 
caused primarily by toxin types A, B, or E, and rarely by F produced by C. botulinum. 
Several related clostridial species can produce botulinum toxins as well; toxin type E can be 
produced by C. butyricum and type F can be produced by C. baratii. Although most strains 
produce a single toxin type, rare mixed toxin type strains have been identified that produce 
two types of toxin (i.e., Ba, Ab, Bf, and Af, with capital letter denoting predominant toxin 
type).
CDC categorises human botulism cases into four acquisition categories: foodborne, which 
results from the consumption of foods containing pre-formed botulinum toxin; wound, 
which occurs when C. botulinum spores germinate under anaerobic conditions within a 
wound and produce toxin; infant intestinal colonisation (hereafter referred to as infant 
botulism), which occurs when ingested C. botulinum spores colonise the intestine, 
germinate, multiply and produce toxin in children aged <1 year; and other/unknown, which 
includes cases in persons aged ≥1 year for whom a thorough investigation reveals no 
suspected exposure to contaminated food and who has no wounds. The other/unknown 
category includes cases of adult intestinal colonisation botulism (caused by intestinal 
colonisation with in-vivo toxin production by C. botulinum), iatrogenic botulism (caused by 
an accidental overdose of therapeutic botulinum toxin), as well as laboratory confirmed 
botulism cases with no known cause. Although foodborne and wound botulism can occur in 
children aged <1 year, almost all cases in this age group occur through intestinal 
colonisation (Armada et al., 2003). Previous epidemiologic investigations of botulism have 
linked higher mortality to age ≥60 years, type A or E versus type B toxin and non-infant 
acquisition categories, but these studies did not assess or control for the interrelationships of 
these variables (Hughes et al., 1981; Woodruff et al., 1992; Centers for Disease Control and 
Prevention, 1998). CDC botulism surveillance data was analysed to describe mortality trends 
1California and Alaska authorise botulinum antitoxin release for non-infant cases within their respective jurisdictions, independently 
of CDC.
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and factors associated with botulism mortality since 1975 and to identify the patient groups 
that might benefit from specific, targeted efforts to further reduce mortality.
2 Methods
States report to CDC demographic information (e.g., age and gender), date of onset, 
acquisition category, toxin type and outcome for all cases meeting the Council for State and 
Territorial Epidemiologists’ (CSTE) botulism case definition (CSTE, 2010). Foodborne, 
wound, infant and other/unknown acquisition categories were categorised by CDC using the 
CSTE botulism case definitions (CSTE, 2010; Centers for Disease Control and Prevention, 
2012). Adult intestinal colonisation botulism and iatrogenic botulism were included in the 
‘other/unknown’ botulism category because the small numbers of cases in each category 
precluded in-depth analysis and for consistency with the CSTE case definition. For this 
analysis, non-infant botulism cases were those classified as foodborne, wound, or other/
unknown. Six cases of botulism occurring in persons <1 year of age were categorised as 
foodborne botulism due to evidence indicating that these cases were foodborne. Toxin type 
was determined through laboratory testing at state public health laboratories and/or CDC via 
mouse bioassay of serum, stool, wound and/or food specimens (Hatheway, 1988). Mixed 
and unknown toxin types were excluded from analyses by toxin type. Mixed toxin types 
were excluded from analyses because there were just 16 cases. Unknown toxin types can 
occur when clinical specimens are of insufficient quantity. This prevents toxin typing via the 
mouse bioassay, although botulinum toxicity can still be demonstrated by setting up a 
limited mouse bioassay with a control mouse and a mouse injected with anti-ABE.
Reports received by CDC of cases meeting the CSTE botulism case definition (CSTE, 2010) 
in residents of the USA with onset from 1 January 1975, through 31 December 2009 were 
reviewed. The USA was divided into the following census regions: Midwest (Illinois, Iowa, 
Indiana, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, Wisconsin 
and South Dakota), Northeast (Connecticut, Maine, Massachusetts, New Hampshire, New 
Jersey, New York, Pennsylvania, Rhode Island and Vermont), South (Alabama, Arkansas, 
District of Columbia, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, 
Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia and 
West Virginia) and West (Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, 
Nevada, New Mexico, Oregon, Utah, Washington and Wyoming) (United States Census 
Bureau, http://www.census.gov/). The 35-year study period was divided into seven five-year 
time periods for the purpose of examining changes over time. The data represent all cases 
occurring in the surveillance population, not a sample of cases, so tests of statistical 
significance of changes in mortality ratios by acquisition category over time were not 
applied. Wound botulism was not analysed by time until 1995 because of low numbers of 
reported wound botulism prior to 1994 (Werner et al., 2000). Due to the very small number 
of cases categorised as other/unknown acquisition, this category was not analysed by time.
Mortality ratios were calculated by dividing the number of deaths by the total number of 
cases with outcome information, overall and within categories of age, gender, acquisition 
category, toxin type, region, and time period. The associations of these categories with 
mortality were measured by calculating odds ratios. Mortality by time period stratified by 
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infant and non-infant botulism was calculated. To measure the strength of association of one 
variable on mortality while accounting for the effects of other variables (i.e., the effect of 
age adjusting for acquisition category, toxin type and time period), adjusted odds ratios were 
calculated with a multivariate logistic regression model using variables that were 
significantly associated (p <0.05) with mortality in bivariate analysis. The final model 
excludes all cases in persons <1 year of age (both infant botulism and the six cases of non-
infant botulism), because the very low mortality in infants obscured the differences between 
non-infant acquisition categories in a preliminary model; as a result, the model compares 
mortality between foodborne, wound and other/unknown acquisition categories. Age 
categories were further collapsed in the multivariate model based on results of the bivariate 
analysis. Region was excluded from the model both because toxin type is strongly related to 
geographic region and because nearly all wound botulism occurs in western states 
(Gangarosa et al., 1971; Werner et al., 2000; Sobel et al., 2004). Records with missing data 
were excluded for analyses of the variable(s) that were missing.
3 Results
During 1975–2009, botulism-related death was reported in 109 (3.0%) of 3,618 botulism 
cases in the USA (Table 1); 435 cases without mortality outcome information and an 
additional 66 cases with unknown or mixed toxin type were excluded from this total and 
subsequent analyses. Of the reported cases, 2,352 (65.0%) were infant botulism, 854 
(23.6%) were foodborne botulism, 359 (9.9%) were wound botulism and 53 (1.5%) were in 
the other/unknown category (Table 1). Among the cases of foodborne botulism, 561 (65.7%) 
were associated with an outbreak of two or more persons. Among the few cases of other/
unknown botulism, 32 were type A (60.4%), 14 were type F (26.4%) and seven were type B 
(13.2%). The other/unknown category accounted for nearly half (48.3%) of all type F cases. 
Most (38, 75%) were reported as botulism of unknown source, ten were reported as 
suspected adult intestinal colonisation botulism (age range 5–83, median 57.5 years; 50% 
toxin type A, 30% toxin type F and 20% toxin type B) and five were reported as iatrogenic 
botulism (age range 34–89, median 52 years; 100% toxin type A).
The bivariate analysis in Table 1 reports associations between each variable and mortality, 
independent of other variables. Botulism mortality generally increased with age and was 
highest among persons ≥80 years (0.7% vs. 34.4%, respectively; OR 45.05; 95% CI 23.49–
86.39) for comparisons to <1 year age group. Males and females had similar mortality (3.2% 
vs. 2.9%, respectively), even when stratified by acquisition category (data not shown). All 
non-infant acquisition categories had significantly higher mortality than the infant botulism 
category (0.8%); mortality was highest among cases classified as other/unknown (22.6%; 
OR 38.0; 95% CI 17.2–83.9), followed by foodborne (7.1%; OR 10.0; 95% CI 5.9–17.0) and 
wound (5.0%; OR 6.9; 95% CI 3.5–13.3). Among the other/unknown cases, one death 
occurred in an adult intestinal colonisation patient (toxin type A) and none occurred in 
iatrogenic botulism patients; 11 deaths among cases of unknown acquisition category were 
reported. Mortality among foodborne botulism patients that were associated with an 
outbreak of two or more persons was lower than among patients that occurred as a single 
occurrence (5.4% vs. 10.4%, OR 0.5; 95% CI 0.30–0.84). When compared with cases of 
toxin type F botulism (13.8%), persons with type A (4.1%; OR 0.3; 95% CI 0.1–0.8), type B 
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(1.4%; OR 0.1; 95% CI 0.0–0.3) and type E (3.5%; OR 0.2; 95% CI 0.1–0.8) had 
significantly lower mortality. Mortality in the Northeast was significantly lower than in the 
Midwest (1.6% vs. 4.2%, respectively; OR 0.4; 95% CI 0.2–0.9). Mortality decreased over 
time and was significantly lower than in 1975–1979 in all time periods from 1985–1989 
onward. However, crude mortality (excluding cases with unknown or mixed toxin type) 
among wound and foodborne cases – and all non-infant cases as a group – increased during 
the last two time periods (Figure 1).
The results of the multivariate logistic regression analysis are shown in Table 2. This 
analysis included 1,260 cases, as it excludes cases with unknown outcome, mixed or 
unknown toxin types, infant botulism cases and six cases of foodborne botulism that 
occurred in persons <1 year. Mortality increased with age and was highest among persons 
≥80 (34.4%, vs. 3.8% in 1–49 year-old group; adjusted OR = 17.1; 95% CI 6.9–45.2) when 
adjusting for the effects of acquisition category, toxin type and time period on mortality. 
Foodborne botulism was less likely than other/unknown forms to result in death (adjusted 
OR = 0.3; 95% CI 0.1–0.8) when adjusting for the effects of age group, toxin type and time 
period on mortality. Wound botulism also had lower, though not statistically significantly 
lower, mortality than botulism transmitted by other/unknown mechanism (adjusted OR = 
0.4; 95% CI 0.2–1.2) when adjusting for the effects of age group, toxin type and time period 
on mortality. There were no significant differences in mortality by toxin type when adjusting 
for the effects of age group, acquisition category and time period on mortality. Mortality was 
lower during 1995–1999 and 2000–2004 than during 1975–1984 (3.3% vs. 9.6%, 
respectively; adjusted OR = 0.2; 95% CI 0.1–0.7 and 5.8% vs. 9.6%, respectively; adjusted 
OR = 0.3; 95% CI 0.1–0.7; respectively) when adjusting for the effects of age group, 
acquisition category and toxin type on mortality.
4 Discussion
This large study of botulism mortality, the first to include comparisons of all major 
acquisition categories and the four toxin types that cause human illness, reveals important 
differences in mortality risk related to the mechanism of acquisition and patient age. With 
increasing diagnosis of infant botulism, for which mortality has always been very low, US 
botulism mortality decreased during 1975–2009, with an overall mortality of 3.0 per 100 
cases. However, these summary results mask important differences in mortality between 
acquisition categories. Mortality for non-infant botulism was consistently higher than infant 
mortality and, though it was lower in 1995–2004 than in 1975–1979, it increased somewhat 
during the last decade of the study. The recent increase appears to be due to an increasing 
proportion of cases in older adults, in whom mortality is quite high. Mortality approached 
35% among persons aged ≥80 years and age was strongly and independently associated with 
mortality, even when excluding infants; similar patterns have been reported previously 
(Tacket et al., 1984; Fagan et al., 2011b). Therefore, efforts aimed at reducing botulism 
mortality should specifically target non-infant acquisition categories and older patients.
Among non-infant acquisition categories, other/unknown cases had the highest mortality. 
The other/unknown categorisation includes intestinal colonisation patients, who generally 
lack typical epidemiologic clues to botulism and in whom; therefore, diagnosis and 
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treatment may be delayed (Fagan et al., 2011a; Filozov et al., 2012; Sheppard et al., 2012). 
The other/unknown category includes a higher percentage of type F botulism cases than 
other categories (Gupta et al., 2005). Some of the cases/deaths in the other/unknown 
acquisition category may have been due to unrecognised adult intestinal colonisation. 
Heptavalent botulinum antitoxin, the only botulinum antitoxin effective for treating type F 
botulism, was not available as first-line treatment for non-infant cases until March 2010, 
which may also contribute to the higher overall mortality in type F patients. Although it may 
be presumed that patients with iatrogenic botulism would be under ongoing medical 
supervision and therefore at lower risk of death, four of the five iatrogenic cases included in 
the other/unknown category received injections of a highly concentrated, unlicensed 
preparation of botulinum toxin A; although it is estimated that these patients may have 
received doses 2,857 times the estimated lethal injected dose (Chertow et al., 2006), none of 
the patients died.
In this study, mortality was significantly associated with toxin type in bivariate analyses only 
and was highest in types A and F botulism. Type A disease has been previously reported to 
be more severe than type B or E disease (Hughes et al., 1981; Woodruff et al., 1992) and 
type F cases have been described as following a characteristically fulminant course with 
rapid progression to respiratory failure and paralysis (Gupta et al., 2005). Our results 
indicate that the observed mortality differences among toxin types could be influenced by 
other factors such as age or acquisition category, which itself implies certain characteristics 
of the at-risk population. For instance, type F botulism is thought to typically occur as 
intestinal colonisation among adults with pre-existing gastrointestinal pathology or recent 
antimicrobial use, which raises the possibility that the relatively severe illness described in 
these patients is reflective of poorer underlying health status than other groups of botulism 
patients. Still, our results should not be interpreted as excluding actual syndromic 
differences among toxin types on the basis of differences in their molecular targets or half-
lives (Simpson, 2004).
Prompt administration of botulinum antitoxin has been shown to decrease mortality (Tacket 
et al., 1984). For two reasons, we were unable to confirm these results. First, although 
complete data on antitoxin release are available, information about actual administration of 
antitoxin was rarely available for cases in the early years of the study. Second, even when 
information on antitoxin administration was available, the time between symptom onset and 
administration was usually not recorded.
The data on mortality were complete for almost 90% of cases; this low rate of missing data 
lends credence to the results showing strong association of older age and acquisition 
category with mortality. Ethnicity and race were not included in the analysis because these 
data were missing for most cases. Because suspect botulism cases constitute both a medical 
and public health emergency and because confirmatory testing and specific treatment for 
suspect botulism patients can only be obtained through public health agencies, our 
surveillance database should include all or almost all diagnosed cases. However, mild cases 
likely occurred that did not result in a visit to a physician and diagnoses were likely missed 
in both mild and severe cases; following the detection of one large foodborne outbreak, 36 
previously unrecognised cases were identified; these patients had been misdiagnosed with 
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myasthenia gravis, psychiatric disorders, stroke and others (St. Louis et al., 1988). The 
inclusion of cases involved in foodborne outbreaks of two or more persons in this analysis 
may lead to an underestimate of the mortality rate of foodborne botulism as compared to 
other botulism acquisition categories, as the definition of foodborne botulism includes 
persons with clinically compatible cases who ate the same food as a laboratory-confirmed 
case, but whose illnesses may not have been laboratory-confirmed (i.e., milder cases). The 
inclusion of milder cases may help explain why the mortality among foodborne cases that 
occur in an outbreak of two or more persons is lower than those that occur as an isolated 
case. Alternatively, clustered cases are more rapidly diagnosed as botulism if more than one 
patient is concurrently hospitalised with symptoms consistent with botulism, which could 
lead to earlier treatment (Newkirk and Hedberg, 2012). Deaths occurring long after the 
initial diagnosis may not be captured by the surveillance system.
The findings described in the multivariate model, such as increased mortality with age and 
lower mortality due to foodborne botulism are likely broadly generalisable to other 
countries. However, mortality rates may vary by country depending on the availability of 
supportive care and antitoxin, as well as variation in the predominant acquisition 
category/ies of botulism.
Additional investigation is warranted to understand the associations of age and acquisition 
category with botulism mortality. A possible explanation for higher mortality among older 
patients might be the increased presence of underlying comorbidities that could adversely 
affect survival; however additional information about comorbidities of botulism patients is 
needed to further evaluate this hypothesis. Our data also lacked detailed information about 
duration of illness at which death occurred, or contributing factors to botulism deaths (e.g., 
ventilator-associated pneumonia) that support additional hypothesis generation regarding our 
findings. Collection of more complete clinical information, which is now mandated by FDA 
as part of the pre-licensure evaluation of investigational heptavalent botulinum antitoxin, 
could help address these knowledge gaps (Centers for Disease Control and Prevention, 
2010). Efforts to prevent the occurrence of botulism may include targeted education about 
safe food practices, particularly among home-canners, persons who prepare and consume 
Alaska Native foods and older adults. Injection drug use should be discouraged and 
strategies for harm reduction among injection drug users considered. Training physicians in 
the early recognition of cases and the need to promptly administer antitoxin is also important 
to minimise mortality.
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Figure 1. Botulism mortality (deaths per 100 cases) by time period and acquisition category, 
USA, 1975–2009 (n = 3,618)*, **
Notes: *Excludes cases with unknown outcome (n = 435) and cases with unknown or mixed 
toxin type (n = 66),
**Due to the very small number of cases categorised as other/unknown (n = 53), the other/
unknown acquisition category was not analysed by time period
***The non-infant category includes all botulism cases classifed as foodborne, wound and 
other/unknown.
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Table 1
Botulism mortality by demographic subgroups, acquisition category, toxin type, region and time period, toxin 
types A, B, E and F, USA 1975–2009 (n = 3,618)*
Died Survived Percent mortality OR (95% CI)
Age (years)
 <1 17 2,327 0.7 Referent
 1–9 3 40 7.0 10.3 (2.9–36.4)
 10–19 2 56 3.4 4.9 (1.1–21.7)
 20–29 6 154 3.6 5.3 (2.1–13.7)
 30–39 8 245 3.2 4.5 (1.91–10.5)
 40–49 11 262 4.0 5.8(2.7–12.4)
 50–59 23 200 10.3 15.4 (7.2–33.0)
 60–69 12 107 10.1 15.4 (7.2–33.0)
 70–79 15 58 20.6 35.4 (16.9–74.3)
 ≥80 11 21 34.4 71.7 (30.0–171.4)
 Unknown 1 39 2.5 4.4 (0.6–34.2)
Gender
 Male 59 1,805 3.2 Referent
 Female 50 1,696 2.9 0.9 (0.6–1.3)
 Unknown 0 8 0.0 0.8 (0.0–15.1)
Acquisition category
 Infant 18 2,334 0.8 Referent
 Foodborne 61 793 7.1 10.0 (5.9–17.0)
 Wound 18 341 5.0 6.9 (3.5–13.3)
 Other/unknown 12 41 22.6 38.0 (17.2–83.9)
Toxin type
 F 4 25 13.8 Referent
 A 77 1,826 4.1 0.3 (0.1–0.8)
 B 20 1,437 1.4 0.1 (0.0–0.3)
 E 8 221 3.5 0.2 (0.1–0.8)
Region**
 Midwest 12 272 4.2 Referent
 Northeast 8 493 1.6 0.4 (0.2–0.9)
 South 19 510 3.6 0.8 (0.4–1.8)
 West 69 2,232 3.0 0.7 (0.4–1.3)
Time period
 1975–1979 24 315 7.1 Referent
 1980–1984 27 487 5.3 0.7 (0.4–1.3)
 1985–1989 8 474 1.7 0.2 (0.1–0.5)
 1990–1994 9 447 2.0 0.3 (0.1–0.6)
 1995–1999 10 570 1.7 0.2 (0.1–0.5)
 2000–2004 12 604 2.0 0.3 (0.1–0.5)
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Died Survived Percent mortality OR (95% CI)
 2005–2009 19 612 3.0 0.4 (0.2–0.8)
Notes:
*
Excludes cases for whom outcome is not known (n = 435) and cases with unknown or mixed toxin type (n = 66),
**
Excludes three cases from Puerto Rico; n = 3,615
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Table 2
Multivariate logistic regression analysis of botulism mortality among persons ≥1 year of age, toxin types A, B, 
E and F, USA 1975–2009*
Died Survived Percent mortality Adjusted OR (95% CI)**
Age (years)
 1–49*** 29 744 3.8 Referent
 50–69 35 307 10.2 3.2 (1.9–5.5)
 70–79 15 58 20.6 7.5 (3.5–15.9)
 ≥80 11 21 34.4 17.1 (6.9–45.2)
Acquisition category
 Other/unknown 12 41 22.6 Referent
 Foodborne 61 787 7.2 0.3 (0.1–0.8)
 Wound 18 341 5.0 0.4 (0.2–1.2)
Toxin type
 F 3 18 14.3 Referent
 A 68 757 8.2 1.6 (0.3–7.3)
 B 12 175 6.4 1.0 (0.2–5.3)
 E 8 219 3.5 0.7 (0.1–3.8)
Time period
 1975–1979 21 193 9.8 Referent
 1980–1984 18 130 12.2 1.4 (0.6–2.8)
 1985–1989 8 147 5.2 0.5 (0.2–1.3)
 1990–1994 8 130 5.8 0.5 (0.2–1.2)
 1995–1999 7 205 3.3 0.2 (0.1–0.7)
 2000–2004 10 161 5.9 0.3 (0.1–0.7)
 2005–2009 19 203 8.6 0.5 (0.2–1.1)
Notes:
*
Excludes cases for whom outcome is not known (n = 435), cases with unknown or mixed toxin type (n = 66), infant botulism acquisition category 
(n = 2,352) and foodborne cases that occurred in persons <1 year (n = 6),
**
The adjusted OR measures the effect between a predictor variable (i.e., age) and mortality while adjusting for other predictor variables (i.e., 
acquisition category, toxin type and time period),
***
Does not equal the sum of age groups 1–9…40–49 because 14 infant botulism cases were reported to CDC as occurring in one year olds; all 14 
cases occurred in infants aged 63 weeks or younger (median 53 weeks)
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